These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30824283)

  • 1. Creativity related to dopaminergic treatment: A multicenter study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Desojo LV
    Parkinsonism Relat Disord; 2019 Jun; 63():169-173. PubMed ID: 30824283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased creativity associated with dopamine agonist therapy: A case report and short review of the literature.
    Thakolwiboon S; Karukote A; Julayanont P; Wilms H
    Clin Neurol Neurosurg; 2022 May; 216():107237. PubMed ID: 35395562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impulsive-compulsive syndrome in Parkinson's disease].
    Nikitina AV; Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
    Seeman P
    Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome.
    Schreglmann SR; Gantenbein AR; Eisele G; Baumann CR
    Parkinsonism Relat Disord; 2012 Feb; 18(2):207-9. PubMed ID: 22030321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.
    Antonini A; Chaudhuri KR; Boroojerdi B; Asgharnejad M; Bauer L; Grieger F; Weintraub D
    Eur J Neurol; 2016 Oct; 23(10):1556-65. PubMed ID: 27425586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Devotion to painting in a Parkinson's disease patient].
    Matsuda N; Kobayashi S; Ugawa Y
    Rinsho Shinkeigaku; 2018 Dec; 58(12):756-760. PubMed ID: 30487358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists.
    Bienfait KL; Menza M; Mark MH; Dobkin RD
    J Clin Neurosci; 2010 Apr; 17(4):539-40. PubMed ID: 20171891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity.
    Kulisevsky J; Pagonabarraga J; Martinez-Corral M
    J Neurol; 2009 May; 256(5):816-9. PubMed ID: 19240966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risky business of dopamine agonists in Parkinson disease and impulse control disorders.
    Claassen DO; van den Wildenberg WPM; Ridderinkhof KR; Jessup CK; Harrison MB; Wooten GF; Wylie SA
    Behav Neurosci; 2011 Aug; 125(4):492-500. PubMed ID: 21604834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.
    Voon V; Schoerling A; Wenzel S; Ekanayake V; Reiff J; Trenkwalder C; Sixel-Döring F
    BMC Neurol; 2011 Sep; 11():117. PubMed ID: 21955669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.
    Cornelius JR; Tippmann-Peikert M; Slocumb NL; Frerichs CF; Silber MH
    Sleep; 2010 Jan; 33(1):81-7. PubMed ID: 20120624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impulse Control and Related Disorders in Parkinson's Disease.
    Weintraub D; Claassen DO
    Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
    Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
    Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
    Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list.
    Fusaroli M; Raschi E; Contin M; Sambati L; Menchetti M; Fioritti A; Poluzzi E
    Parkinsonism Relat Disord; 2021 Sep; 90():79-83. PubMed ID: 34399162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis.
    Garcia-Ruiz PJ
    Front Neurol; 2018; 9():1041. PubMed ID: 30574117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impulse control symptoms in patients with Parkinson's disease: The influence of dopaminergic agonist.
    Vargas AP; Vaz LS; Reuter A; Couto CM; Costa Cardoso FE
    Parkinsonism Relat Disord; 2019 Nov; 68():17-21. PubMed ID: 31621612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions.
    Ramirez-Zamora A; Gee L; Boyd J; Biller J
    Expert Rev Neurother; 2016; 16(4):389-99. PubMed ID: 26923084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.